fludarabine has been researched along with imatinib mesylate in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, F; Beguin, Y; Fillet, G; Frère, P; Herens, C | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Okamoto, S | 1 |
| Korycka, A; Robak, T | 1 |
| Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A | 1 |
| Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR | 1 |
| Ohnishi, K | 1 |
| Baran-Marszak, F; Bornkamm, GW; Fagard, R; Feuillard, J; Gachard, N; Le Clorennec, C; May, E; Najjar, I; Reminieras, L; Youlyouz-Marfak, I | 1 |
| Heimfeld, S; McCune, JS; Ren, AG; Wang, J; Woodahl, EL | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Baran, Y; Bassoy, EY; Oztekin, C | 1 |
| Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M | 1 |
| Acar, H; Aydemir, E; Bayrak, OF; Gulluoglu, S; Ozen, M; Sahin, F; Sevli, S; Yalvac, ME | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
4 review(s) available for fludarabine and imatinib mesylate
| Article | Year |
|---|---|
[Evidence-based therapy for chronic leukemia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine | 2003 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine | 2011 |
2 trial(s) available for fludarabine and imatinib mesylate
| Article | Year |
|---|---|
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Recombination, Genetic; Treatment Outcome; Vidarabine | 2011 |
12 other study(ies) available for fludarabine and imatinib mesylate
| Article | Year |
|---|---|
Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation; Vidarabine; Whole-Body Irradiation | 2002 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine | 2003 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Brefeldin A; Cell Line, Tumor; Cisplatin; Dactinomycin; Doxorubicin; Humans; Imatinib Mesylate; Interferons; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-mdm2; Pyrimidines; STAT1 Transcription Factor; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Imatinib inhibition of fludarabine uptake in T-lymphocytes.
Topics: Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Drug Interactions; Humans; Imatinib Mesylate; In Vitro Techniques; Piperazines; Pyrimidines; Thioinosine; Vidarabine | 2008 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caspase 3; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Piperazines; Pyrimidines; Vidarabine | 2010 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
The effects of chemotherapeutic agents on differentiated chordoma cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Chordoma; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Imatinib Mesylate; Methotrexate; Piperazines; Pyrimidines; Vidarabine; Vincristine | 2011 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |